Dermatological Drugs Market Forecast 2020-2030

1. Report Overview 1.1 Global Dermatological Drugs Market Overview 1.2 Overview of Findings 1.3 Structure of the Report 1.4 Global Dermatological Drugs Market Segmentation 1.5 Why You Should Read This Report 1.6 How This Report Delivers 1.7 Key Questions Answered by This Analytical Report 1.8. Who is This Report For? 1.9 Methodology 1.10 Associated Visiongain Reports 1.11 About Visiongain 2. Introduction to Dermatological Drugs 2.1 The Pharmaceutical Industry: A Brief Introduction 2.2 An Introduction to Dermatology 2.2.1 The Structure of Skin, Hair, and Nails 2.2.2 Hair and Nails 2.2.3 Sweat and Sebaceous Glands 2.2.4 Functions of the Skin 2.3 Common Skin Diseases 2.3.1 Acne: The Most Common Skin Disease 2.3.1.1 Acne: Epidemiology 2.3.1.2 Acne: Causes and Pathogenesis 2.3.1.3 Acne: Treatment 2.3.2 Dermatitis: Inflammation of the Skin 2.3.2.1 Atopic Dermatitis 2.3.2.2 Contact Dermatitis 2.3.2.3 Seborrhoeic Dermatitis 2.3.2.4 Nummular Dermatitis 2.3.2.5 Perioral Dermatitis 2.3.3 Psoriasis: A Complex Multi-Factorial Disease 2.3.4 Rosacea: Vascular Instability 2.3.5 Alopecia: Excessive Shedding of Hair 2.4 Skin Infections: A Serious Healthcare Threat 2.4.1 Bacterial Skin Infections 2.4.2 Fungal Skin Infections 2.4.3 Viral Skin Infections 2.5 Common Skin Treatments 2.5.1 Creams and Semisolid Emulsions 2.5.2 Ointments 2.5.3 Lotions 2.5.4 Solutions 2.5.5 Occlusive Therapy 2.5.6 Cleansing Agents 2.5.7 Powders and Hydrophilic Polymer 2.5.8 Anti-Infective Agents 2.5.9 Anti-Inflammatory Agents 2.6 Phases of Clinical Trials 2.7 Dermatological Drugs: Market Definition in this Report 3. Global Dermatological Drugs Market by Indication 2020-2030 3.1 The Global Dermatological Drugs Market: Market Overview 3.2 Categorisation of the Global Dermatological Drugs Market 3.3 The Global Dermatological Drugs Market in 2019 3.4 The Global Dermatological Drugs Market: Market Forecast 2020-2030 3.5 Changing Market Shares by Segment 2020-2030 4. The Psoriasis Drugs Market: Market Analysis and Forecast 2020-2030 4.1 Psoriasis Treatments: The Dominance of Biologics 4.1.1 Leading Products in the Psoriasis Drugs Market, 2019 4.2 Psoriasis: Market Trends and Developments, 2019 4.2.1 Biological Drugs in Psoriasis Treatment: A Brief Overview 4.2.2 Issues around Patent Protection, the Threat of Biosimilars and Pricing 4.2.3 Biosimilars and Interchangeables 4.2.3.1 Extrapolation of indications 4.2.3.2 Biosimilar interchangeability in the EU 4.2.3.3 Biosimilar guidance in the US 4.2.3.4 The Disadvantages of Biologics in Psoriasis Treatment 4.3 Psoriasis Drugs: Market Forecast 2020-2030 4.3.1 Psoriasis Drugs: Changing Market Shares by Leading Drugs 2020-2030 4.4 Leading Drugs Used in the Treatment of Psoriasis 4.4.1 Humira (adalimumab) - AbbVie 4.4.1.1 Humira: Historical Sales Analysis, 2010-2017 4.4.1.2 Humira: Sales Forecast 2020-2030 4.4.1.3 Future Prospects for Biosimilar Versions of Humira 4.4.2 Stelara (ustekinumab) - Johnson & Johnson 4.4.2.1 Stelara New Market Leader, Ahead of Humira 4.4.2.2 Stelara: Historical Sales Analysis, 2010-2017 4.4.2.3 Stelara: Sales Forecast 2020-2030 4.4.2.4 Intensifying Competition for Stelara 4.4.3 Enbrel (etanercept) - Amgen/ Pfizer/ Takeda 4.4.3.1 Enbrel: Co-Promotions and Marketing Rights 4.4.3.2 Enbrel: Historical Sales Analysis, 2009-2017 4.4.3.3 Enbrel: Patent Expiries and Potential Competition, 2020-2030 4.4.3.4 Patent Litigation with Sandoz Over Enbrel 4.4.3.5 Enbrel: Sales Forecast 2020-2030 4.4.3.6 Enbrel Auto-injector Pens: A Driver of Growth in Recent Years 4.4.3.7 Competition from Other Drugs 4.4.3.8 Biosimilar Competition for Enbrel 4.4.4 Remicade (infliximab) - Johnson & Johnson 4.4.4.1 Remicade: Historical Sales Analysis, 2009-2017 4.4.4.2 Remicade: Patent Expiries and Potential Competition, 2020-2030 4.4.4.3 Remicade: Sales Forecast 2020-2030 4.4.5 Taltz (ixekizumab) - Eli Lilly 4.4.5.1 Taltz: Sales Forecast 2020-2030 4.4.6 Otezla (apremilast) - Celgene 4.4.6.1 Otezla: Sales Forecast 2020-2030 4.4.7 Cosentyx (secukinumab) - Novartis 4.4.7.1 Cosentyx: Sales Forecast 2020-2030 4.4.8 Other Psoriasis Drugs 4.4.8.1 Cimzia (certolizumab) - UCB 4.4.8.2 Sorilux (calcipotriene foam) - GSK 4.4.8.3 Siliq (brodalumab) - AstraZeneca/ LEO Pharma 4.4.8.4 Other Psoriasis Drugs: Sales Forecast 2020-2030 4.5 Psoriasis Drugs Market: Summary 5. Skin Infection Drugs Market: Market Analysis and Forecast 2020-2030 5.1 Skin Infection Drugs: Abundant Growth Opportunities 5.1.1 Leading Products in the Skin Infection Drugs Market, 2019 5.2 Skin Infection Drugs: Market Forecast 2020-2030 5.2.1 Skin Infection: Changing Market Shares by Leading Drugs 2020-2030 5.3 Leading Drugs Used in the Treatment of Skin Infections 5.3.1 Cubicin (daptomycin) - Cubist Pharmaceuticals/ Merck & Co 5.3.2 Acquisition by Merck & Co 5.3.3 Generic Competition for Cubicin 5.3.4 Cubicin: Sales Forecast 2020-2030 5.3.5 Lifecycle Management Strategies for Cubicin 5.4 Zyvox (linezolid) - Pfizer 5.4.1 Zyvox: Historical Sales Analysis, 2010-2017 5.4.2 Zyvox: Sales Forecast 2020-2030 5.4.3 The Threats to Zyvox Sales from Competing New Drugs 5.5 Canesten (clotrimazole) - Bayer 5.5.1 Canesten: Historical Sales Analysis, 2011-2017 5.5.2 Canesten: Sales Forecast 2020-2030 5.6 Valtrex (valaciclovir) - GSK 5.6.1 Valtrex: Historical Sales Analysis, 2010-2017 5.6.2 Valtrex: Sales Forecast 2020-2030 5.7 Sivexto 5.7.1 Sivexto: Sales Forecast 2020-2030 5.8 Lamisil (terbinafine) - Novartis 5.8.1 Lamisil Patent Expiry 5.8.2 Lamisil Sales Affected by Novartis Manufacturing Problems 5.8.3 Lamisil: Sales Forecast 2020-2030 5.9 Other Skin Infection Drugs 5.9.1 Dalvance (dalbavancin) - Durata Therapeutics 5.9.2 Jublia (efinaconazole) - Valeant 5.9.3 Kerydin (tavaborole) - Anacor 5.9.4 Zovirax (acyclovir) - Valeant/GSK 5.9.4.1 Valeant Acquires Zovirax in US and Canada 5.9.4.2 Mylans Generic Zovirax and Actavis Authorised Generic 5.9.5 Other Skin Infection Drugs: Sales Forecast 2020-2030 5.10 Skin Infection Drugs: Market Summary 6. Acne Drugs Market: Market Analysis and Forecast 2020-2030 6.1 Acne Drugs: A Diversified Market 6.1.1 Leading Products in the Acne Drugs Market, 2019 6.2 Acne Drugs Market: Recent Trends and Developments 6.2.1 The Rise of Combination Therapies in Acne Treatment 6.2.2 Oral Contraceptives in Treating Acne 6.2.3 The Threat of Generic Competition in the Acne Drugs Market 6.3 Acne Drugs: Market Forecast 2020-2030 6.3.1 Acne Drugs: Changing Market Shares by Leading Drugs 2020-2030 6.4 Leading Drugs in the Acne Drugs Market 6.4.1 Epiduo (adapalene/benzoyl peroxide) - Galderma/ Nestlé Skin Health 6.4.1.1 Epiduo: Sales Forecast 2020-2030 6.4.1.2 Galderma Settlement Agreement over Generic Epiduo 6.4.1.3 Paediatric Approval for Epiduo 6.4.2 Solodyn (minocycline) - Valeant 6.4.2.1 Solodyn: Sales Forecast 2020-2030 6.4.2.2 Antitrust Action over Solodyn Pay-For-Delay Deals 6.4.2.3 Impax and Medicis Collaborating on Advanced Solodyn 6.4.2.4 Medicis and Lupin Settle 6.4.3 Claravis (isotretinoin) - Teva 6.4.3.1 Claravis: Sales Forecast 2020-2030 6.4.4 Aczone (dapsone) - Allergan 6.4.4.1 Aczone: Sales Forecast 2020-2030 6.4.5 Retin-A Micro - Bausch Health 6.4.5.1 Retin-A Micro: Sales Forecast 2020-2030 6.4.6 Absorica/Epuris (CIP-isotretinoin) - Cipher/Sun Pharma 6.4.6.1 Absorica/Epuris: Sales Forecast 2020-2030 6.4.7 Ziana (clindamycin/tretinoin) - Valeant Pharmaceuticals International 6.4.7.1 Valeants Patent Settlement with Actavis over Ziana 6.4.7.2 Ziana: Sales Forecast 2020-2030 6.4.8 Acanya (clindamycin/benzoyl peroxide) - Dow /Valeant 6.4.8.1. Actavis Claims First-to-File Exclusivity for its Acanya 6.4.8.2 Legal Battles Involving Dow/Valeant, Perrigo, and 6.4.8.3 Acanya: Sales Forecast 2020-2030 6.4.9 Other Acne Drugs 6.4.9.1 Doryx (doxycycline) - Actavis/Mayne Pharma 6.4.9.1.1 Lifecycle Management Strategies for Doryx 6.4.9.1.2 Divestment Agreement with Mayne Pharma 6.4.9.1.3 Generic Competition for Doryx 6.4.9.2 Amnesteem (isotretinoin) - Mylan 6.4.9.2.1 Amnesteem: Financial Analysis 6.4.9.3 Diane (cyproterone/ethinyl estradiol) - Bayer 6.4.9.4 Duac (clindamycin/benzoyl peroxide) - 6.4.9.5 Veltin (tretinoin/clindamycin) - GSK 6.4.9.6 Other Acne Drugs: Sales Forecast 2020-2030 6.5 Acne Drugs: Market Summary 7. Dermatitis Drugs Market: Market Analysis and Forecast 2020-2030 7.1 Dermatitis Drugs: High Generic Penetration 7.1.1 Leading Products in the Dermatitis Drugs Market, 2019 7.2 Dermatitis Drugs: Market Forecast 2020-2030 7.2.1 Dermatitis Drugs: Changing Market Shares by Leading Drugs 2020-2030 7.3 Leading Drugs in the Dermatitis Drugs Market 7.3.1 Bepanthen (dexpanthenol)/ Bepanthol - Bayer 7.3.1.1 Bepanthen: Sales Forecast 2020-2030 7.3.2 Elocon (mometasone) - Merck & Co 7.3.2.1 Elocon: Sales Forecast 2020-2030 7.3.3 Protopic (tacrolimus) - LEO Pharma 7.3.3.1 Protopic Benefits from Expanded Indication 7.3.3.2 Generic Competition for Protopic 7.3.3.3 Protopic: Sales Forecast 2020-2030 7.3.4 Dermovate -GSK 7.3.4.1 Dermovate: Sales Forecast 2020-2030 7.3.5 Other Dermatitis Drugs: Sales Forecast 2020-2030 7.4 Dermatitis Drugs: Market Outlook 8. Leading National Markets 2020-2030 8.1. Geographical Breakdown of the World Dermatological Drugs Market 8.2 World Dermatological Drugs Market: Regional Forecast 2020-2030 8.2.1 How Will Regional Market Shares Change to 2030? 9. North America Dermatological Drugs Market 2020-2030 9.1. U.S. Dermatological Drugs Market: Trends and Developments 9.1.1. Obamacare Repeal 9.1.2. Legislative Environment Stimulating Biosimilars 9.1.3 Biosimilar Interchangeability guidance in the US 9.1.4 US Dermatological Drugs Market: Market Forecast 2020-2030 9.2. Canada Dermatological Drugs Market: Trends and Developments 10. Europe Dermatological Drugs Market 2020-2030 10.1 Europe Markets: Changing Market Shares by Country, 2020-2030 10.2 Germany 10.2.1 Germany Dermatological Drugs Market: Market Forecast 2020-2030 10.3. France Dermatological Drugs Market Forecast 2020-2030 10.4. U.K. 10.4.1 The Impact of Brexit On the Dermatological Drugs 10.4.2 Pricing and Reimbursement 10.4.3 New Regulatory Body and Clinical Trials 10.4.4 Patent Protection 10.4.5 Research and Funding 10.4.6. U.K. Dermatological Drugs Market Forecast 2020-2030 10.5 Italy 10.5.1 Italy Dermatological Drugs Market Forecast 2020-2030 10.6. Spain Dermatological Drugs Market Forecast 2020-2030 10.7. Rest of Europe Dermatological Drugs Market Forecast 2020-2030 10.7.1 Russia 10.7.1.1 Pharma2020 Strategy - Healthcare and Industry Reform 11. Asia-Pacific Dermatological Drugs Market 2020-2030 11.1 China 11.1.1 Expansion of Healthcare Coverage and Reimbursement in China 11.1.2 Improving Public Perception of Dermatology in China 11.1.3 Price Controls and the Anhui Model 11.1.4 Chinese Dermatological Drugs Market Forecast 2020-2030 11.2. Japan Dermatological Drugs Market: Trends and Developments 11.2.1 The Cost of Treatment in Japan 11.2.2 Japanese Pharmaceutical Industry Regulatory Reform 11.2.3 Japanese Dermatological Drugs Market Forecast 2020-2030 11.3. India 11.3.1 The Effects of the Drug Prices Control Order of 2013 11.3.2 Indias Expansion of Healthcare Provision 11.3.3 Revised Biosimilar Guidelines 11.3.4 Indian Dermatological Drugs Market Forecast 2020-2030 11.4. Rest of Asia-Pacific Dermatological Drugs Market: Trends and Developments 12. Latin America Dermatological Drugs Market 2020-2030 12.1 Brazil 12.1.1 The Growth in Brazils Healthcare Landscape 12.1.2 Clearer Access to Medicines in Brazil 12.1.3 Brazil Dermatological Drugs Market Forecast 2020-2030 12.2. Mexico Dermatological Drugs Market: Trends and 12.3. Rest of Latin America Dermatological Drugs Market: Trends and Developments 13. Middle East & Africa Dermatological Drugs Market 2020-2030 13.1. Saudi Arabia Dermatological Drugs Market Forecast 2020-2030 13.2. South Africa Dermatological Drugs Market Forecast 2020-2030 13.3. Rest of Middle East & Africa Dermatological Drugs Market Forecast 2020-2030 14. Leading Companies in the Dermatological Drugs Market 14.1. Galderma (Nestle Skin Health S.A.) 14.1.1 Galderma: Dermatological Drugs Product Portfolio 14.1.2 Financial Overview 14.1.3. Recent Transactions Summary 14.2. Johnson & Johnson 14.2.1. Johnson & Johnson: Dermatological Drugs Product Portfolio 14.2.2 Financial Overview 14.2.2.1 Pipeline, 2019 14.2.3. Recent Transactions Summary 14.3. GlaxoSmithKline plc 14.3.1 GlaxoSmithKline plc: Dermatological Drugs Portfolio 14.3.2 GlaxoSmithKline plc: Financial Overview 14.3.3 GlaxoSmithKline plc: Recent Transactions Summary 14.4. Pfizer, Inc. 14.4.1 Pfizer, Inc.: Dermatological Drugs Portfolio 14.4.2 Pfizer, Inc.: Financial Overview 14.4.3 Pfizer, Inc.: Recent Developments 14.4.4 Pfizer: Dermatological Drugs Development Pipeline, 2019 14.5.LEO Pharma A/S 14.5.1 LEO Pharma A/S.: Dermatological Drugs Product Portfolio 14.5.2 Financial Overview 14.5.3 Recent Transactions Summary 14.6. AbbVie Inc. 14.6.1 AbbVie Inc.: Dermatological Drugs Product Portfolio 14.6.2 Financial Overview 14.6.3 Recent Transactions Summary 14.7. Novartis AG 14.7.1 Novartis: Dermatological Drugs Portfolio 14.7.2 Novartis: Financial Overview 14.7.3 Novartis: Recent Developments 14.8. Amgen, Inc. 14.8.1 Amgen, Inc.: Dermatological drugs Portfolio 14.8.2 Financial Overview 14.8.3. Recent Transactions Summary 14.9. Merck & Co., Inc. 14.9.1 Merck & Co., Inc.: Dermatological Drugs Portfolio 14.9.2 Merck & Co., Inc.: Financial Overview 14.9.3 Merck & Co., Inc.: Recent Transactions Summary 14.10. Bayer AG 14.10.1 Bayer AG: Dermatological Drugs Portfolio 14.10.2 Bayer AG: Financial Overview 14.10.3 Bayer AG: Recent Transactions Summary 14.11. Celgene Corporation 14.11.1 Celgene Corporation: Dermatological Drugs Product Portfolio 14.11.2 Celgene Corporation: Financial Overview 14.11.3 Celgene Corporation: Recent Transactions Summary 14.12. Bausch Health Companies Inc. 14.12.1 Bausch Health Companies Inc.: Dermatological Drugs Product Portfolio 14.12.2 Bausch Health Companies Inc.: Dermatological Drugs Product Pipeline 14.12.3 Bausch Health Companies Inc.: Financial Overview 14.12.4 Bausch Health Companies Inc.: Recent Developments 14.13. Bristol-Myers Squibb Company 14.13.1 Bristol-Myers Squibb Company: Dermatological Drugs Product Portfolio 14.13.2 Bristol-Myers Squibb Company: Dermatological Drugs Product Pipeline 14.13.3 Bristol-Myers Squibb Company: Financial Overview 14.13.4 Bristol-Myers Squibb Company: Recent Transactions Summary 14.14. Allergan plc 14.14.1 Allergan plc: Dermatological Drugs Product Portfolio 14.14.2 Allergan plc: Financial Overview 14.14.3 Allergan plc: Recent Transactions Summary 14.15. Eli Lilly and Company 14.15.1 Eli Lilly and Company: Dermatological Drugs Product Portfolio 14.15.2 Eli Lilly and Company: Financial Overview 14.15.3 Eli Lilly and Company: Recent Transactions Summary 15. Dermatological Drugs: Research and Development Pipeline, 2020-2030 15.1 Innovative Products Currently in Development Will Drive Growth 15.1.1 New Technology in R&D Pipeline Activities 15.1.1.1 Reformulation 15.1.1.2 Combination Treatments 15.1.1.3 New Mechanisms and Drug Delivery Technologies 15.1.1.4 Potential Market Entrants 15.2 Psoriasis Drugs Development Pipeline, 2019 15.2.1 Psoriasis Drugs in Phase 3 Development or 15.2.1.2 CF101 (Piclidenoson) - Can-Fite BioPharma 15.2.2 Psoriasis Drugs in Phase 2 Development 15.2.2.1 LY3009104 (baricitinib) - Incyte/ Eli Lilly 15.2.2.2 PH-10 (Rose Bengal) - Provectus 15.2.3 Psoriasis Drugs in Phase 1 and Pre-Clinical 15.3 Skin Infection Drugs Development Pipeline, 2019 15.3.1 Drugs in Phase 3 Development for Skin Infections 15.3.1.1 Baxdela (delafloxacin) - Melinta Pharmaceuticals 15.3.1.2 NB-001 - NanoBio Corporation 15.3.1.3 Luliconazole - Topica Pharmaceuticals 15.3.2 Drugs in Phase 2 Development for Skin Infections 15.3.3 Drugs in Phase 1 and Preclinical Pipeline for Skin Infections 15.4 Acne Drugs Development Pipeline, 2019 15.4.1 Drugs in Phase 3 Development for Acne 15.4.1.2 Visonac (photodynamic therapy) - Photocure 15.4.2 Drugs in Phase 2 Development for Acne 15.4.3 Drugs in Phase 1 and Pre-Clinical Development for Acne 15.4.4 A Possible Vaccine for Acne 15.5 Dermatitis Drugs Development Pipeline, 2019 15.5.1 Drugs in Phase 3 Development for Dermatitis 15.5.1.1 Toctino (alitretinoin) - GSK 15.5.1.2 Dermadexin and Pruridexin (P3CGM) - Cipher 15.5.1.3 Dexeryl Cream (glycerol/paraffin emollient) - Pierre 15.5.1.4 REGN668/SAR231893 (dupilumab) - 15.5.2 Drugs in Phase 2 Development for Dermatitis 15.5.3 Drugs in Phase 1 and Preclinical Stages of Development for Dermatitis 15.6 Other Dermatological Drugs Development Pipeline, 2019 15.6.1 Other Dermatological Drugs: Filed or Recently 15.6.1.1 Actikerall (fluorouracil/salicylic acid) - Almirall 15.6.1.2 Ameluz (5-ALA photodynamic therapy) - Biofrontera 15.6.1.3 Mirvaso (brimonidine) - Galderma 15.6.1.4 Picato (ingenol mebutate) - LEO Pharma 15.6.1.5 Xolair (omalizumab) - Novartis/ Roche 15.6.2 Other Dermatological Drugs: Phase 3 Pipeline 15.6.2.1 CD5024 (ivermectin) - Galderma 15.6.2.2 SR-T100 gel (Solanum incanum extract) - G&E 15.6.3 Other Dermatological Drugs: Phase 2 Pipeline 16. Qualitative Analysis of the Dermatological Drugs Market, 2020-2030 16.1 Market Factors Influencing Dermatological Drugs 16.2 SWOT Analysis of the Global Dermatological Drugs Market, 2020-2030 16.2.1 Strengths 16.2.1.1 The High Unmet Clinical Need in Dermatology 16.2.1.2 A Healthy Pipeline of Development-Stage Products 16.2.1.3 Strong Industry-Physician Relationships 16.2.2 Weaknesses 16.2.2.1 Limited Efficacy and Adverse Effects May Impact 16.2.2.2 Patient Adherence - A Major Challenge to 16.2.2.3 Impending Patent Expiries and the Challenges 16.2.3 Opportunities 16.2.3.1 The High-Growth Sectors in Dermatology 16.2.3.2 Personalised Dermatology: Technological Advances in Genomics 16.2.3.3 Advances in Topical Drug Delivery Methods Offers 16.2.3.4 Consolidation within Dermatology - Opportunity for Synergistic Growth? 16.2.4 Threats 16.2.4.1 Uncertainty Surrounding Reimbursement and 16.2.4.2 The Rising Cost of Research and Development 16.2.4.3 Downward Pressures on Drug Prices 16.3 Porters Five Force Analysis of the Global Dermatological Drugs Market, 2020-2030 16.3.1 Threat of New Entrants 16.3.2 Threat of Substitutes 16.3.3 Rivalry among Competitors 16.3.4 Power of Buyers 16.3.5 Power of Suppliers 17. Conclusions 17.1 Overview of Current Market Conditions and Market Forecast, 2020-2030 17.2 Leading Sectors in Dermatological Drugs in 2019 17.3 Leading Regions in the Dermatological Drugs Market in 2019 17.4 Future Outlook for the Various Sectors within the Dermatological Drugs Market, 2020-2030 17.5 What Does the Future Hold for Dermatological Drugs? Appendices Associated Visiongain Reports Global OTC Pharmaceutical Market Forecast 2020-2030 Visiongain Report Sales Order Form About Visiongain Visiongain Report Evaluation Form List of Tables Table 2.1 Clinical Trial Phases, 2019 Table 3.1 Global Dermatological Drugs Market Indication: Revenue ($bn), and Market Share (%), 2019 Table 3.2 Global Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 3.3 Global Dermatological Drugs Market Indication: CAGR (%), 2020-2025, 2025-2030, 2020-2030 Table 4.1 Global Psoriasis Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019 Table 4.2 Global Psoriasis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 4.3 Global Psoriasis Drugs Market by Drugs: Market Share (%), 2020-2025, 2025-2030, 2020-2030 Table 4.4 Global Humira Market Forecast: Revenues ($bn) AGR (%), 2010-2017 Table 4.5 Global Humira Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 4.6 Global Stelara Market Forecast: Revenues ($bn) AGR (%), 2010-2017 Table 4.7 Global Stelara Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 4.8 Global Enbrel Market Forecast: Revenues ($Bn) AGR (%), 2009-2017 Table 4.9 Global Enbrel Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 4.10 Global Remicade Market Forecast: Revenues ($bn) AGR (%), 2009-2017 Table 4.11 Global Remicade Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 4.12 Global Taltz Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 4.13 Global Otezla Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 4.14 Global Cosentyx Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 4.15 Global Others Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2019-2030 Table 5.1 Global Skin Infection Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019 Table 5.2 Skin Infection Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 5.3 Global Skin Infection Drugs Market by Drugs: Market Share (%), 2019, 2025, & 2030 Table 5.4 Global Cubicin Market Forecast: Revenue ($bn) AGR & CAGR (%), 2019-2030 Table 5.5 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), 2010-2017 Table 5.6 Global Zyvox Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 5.7 Global Canesten Market Forecast: Revenues ($bn) AGR (%), 2011-2017 Table 5.8 Global Canesten Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 5.9: Global Valtrex Market Forecast: Revenues ($bn) AGR (%), 2010-2017 Table 5.10 Global Valtrex Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 5.11 Global Sivexto Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 5.12 Global Lamisil Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2019-2030 Table 5.13 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 6.1 Global Acne Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019 Table 6.2 Global Acne Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 6.3 Global Acne Drugs Market by Drugs: Market Share (%), 2019, 2025, 2030 Table 6.4 Global Epiduo Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 6.5 Global Solodyn Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 6.6 Global Claravis Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 6.7 Global Aczone Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 6.8 Global Retin-A Micro Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 6.9 Global Absorica/ Epirus Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 6.10 Global Ziana Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 6.11 Global Acanya/Onexton Market Forecast: Revenues ($Bn) AGR (%), CAGR (%), 2019-2030 Table 6.12 Global Others Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 7.1 Global Dermatitis Drugs Market by Drugs: Revenue ($bn), and Market Share (%), 2019 Table 7.2 Global Dermatitis Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 7.3 Global Dermatitis Drugs Market by Drugs: Market Share (%), 2019, 2025, 2030 Table 7.4 Global Bepanthen/ Bepanthol Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 7.5 Global Elocon Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 7.6 Global Protopic Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 7.7 Global Dermovate Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 7.8 Others Dermatitis Drugs Market Forecast: Revenues ($bn) AGR (%), CAGR (%), 2019-2030 Table 8.1 Global Dermatological Drugs Market by Region: Revenue ($bn), 2019 and 2030 Table 8.2 Global Dermatological Drugs Market Forecast, by Region: Revenues ($ bn), AGR (%), CAGR (%), 2019-2030 Table 8.3 Global Dermatological Drugs Market by Region: Market Share (%), 2019, 2025, & 2030 Table 8.4 Global Dermatological Drugs Market by Region: Market Share (%), 2020, 2025, & 2030 Table 9.1 North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 9.2 North America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 9.3 U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 9.4 Canada Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 10.1 Global Dermatological Drugs Market by Country/Sub-region: Revenue ($bn) and Market Share (%), 2019 Table 10.2 Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 10.3 Europe Dermatological Drugs Market Forecast, By Country: Revenues ($ bn), AGR (%), CAGR (%), 2019-2030 Table 10.4 Europe Dermatological Drugs Market by Country/Sub-region: Market Share (%) 2019, 2025, & 2030 Table 10.5 Germany Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 10.6 France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 10.7 U.K. Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 10.8 Italy Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 10.9 Spain Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 10.10 Rest of Europe Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 11.1 Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 11.2 Asia-Pacific Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 11.3 China Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 11.4 Japan Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 11.5 India Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 11.6 Rest of Asia-Pacific Dermatological Drugs Market Forecast, 2019-2030 ($ bn, AGR %, CAGR %) Table 12.1 Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 12.2 Latin America Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 12.3 Brazil Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 12.4 Mexico Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 12.5 Rest of Latin America Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 13.1 Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 13.2 Middle East & Africa (MEA) Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 13.3 Saudi Arabia Dermatological Drugs Market Forecast, By Country: Revenues ($bn), AGR (%), CAGR (%), 2019-2030 Table 13.4 South Africa Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 13.5 Rest of MEA Dermatological Drugs Market Forecast, 2019-2030 ($bn, AGR %, CAGR %) Table 14.1 Galderma: Overview, 2019 Table 14.2. Johnson & Johnson: Overview, 2019 Table 14.3 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017 Table 14.4 GlaxoSmithKline plc: Overview, 2019 Table 14.5 GlaxoSmithKline plc: Revenue ($m), 2014-2018 Table 14.6 GlaxoSmithKline: Dermatological Drugs Pipeline, 2019 Table 14.7 Pfizer, Inc.: Overview, 2019 Table 14.8 Pfizer, Inc.: Revenue ($m), 2015-2018 Table 14.9 LEO Pharma A/S: Overview, 2019 Table 14.10 LEO Pharma A/S: Revenue ($m), AGR (%), 2014-2018 Table 14.11 AbbVie Inc.: Overview, 2019 Table 14.12 AbbVie Inc.: Revenue ($m), AGR (%), 2014-2018 Table 14.13 Novartis: Overview, 2019 Table 14.14 Novartis: Revenue ($m), AGR (%), 2014-2018 Table 14.15 Amgen, Inc.: Overview, 2019 Table 14.16 Amgen, Inc.: Revenue ($m), AGR (%), 2014-2018 Table 14.17 Merck & Co., Inc.: Overview, 2019 Table 14.18 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018 Table 14.19 Bayer AG: Overview, 2019 Table 14.20 Bayer AG: Revenue ($m), AGR (%), 2014-2018 Table 14.21 Celgene Corporation: Overview, 2019 Table 14.22 Celgene Corporation: Revenue ($m), AGR (%), 2014-2018 Table 14.23 Bausch Health Companies Inc.: Overview, 2019 Table 14.24 Bausch Health Companies Inc.: Revenue ($m), AGR (%), 2014-2018 Table 14.25 Bristol-Myers Squibb Company: Overview, 2019 Table 14.26 Bristol-Myers Squibb Company: Revenue ($m), AGR (%), 2014-2018 Table 14.27 AbbVie Inc.: Overview, 2019 Table 14.28 Allergan plc: Revenue ($m), AGR (%), 2014-2018 Table 14.29 Eli Lilly and Company: Overview, 2019 Table 14.30 Eli Lilly and Company: Revenue ($m), AGR (%), 2014-2018 Table 15.1 Psoriasis Drugs Pipeline: Phase 3 Drugs, 2019 Table 15.2 Psoriasis Drugs Pipeline: Phase 2 Drugs, 2018 Table 15.3 Psoriasis Drugs Pipeline: Phase 1 Drugs, 2018 Table 15.4 Skin Infections Drugs Pipeline: Phase 3 Drugs, 2019 Table 15.5 Skin Infections Drugs Pipeline: Phase 2 Drugs, 2019 Table 15.6 Acne Drugs Pipeline: Phase 3 Drugs, 2019 Table 15.7 Acne Drugs Pipeline: Phase 2 Drugs, 2019 Table 15.8 Dermatitis Drugs Pipeline: Phase 3 Drugs, 2019 Table 15.9 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2019 Table 15.10 Other Dermatological Drugs Pipeline: Filed or Recently Launched Drugs, 2019 Table 15.11 Other Dermatological Drugs Pipeline: Phase 3 Drugs, 2019 Table 15.12 Dermatitis Drugs Pipeline: Phase 2 Drugs, 2019 Table 16.1 SWOT Analysis of the Global Dermatological Drugs Market, 2020-2030 Table 17.1 Global Dermatological Drugs Market Forecast: Revenue ($bn), and CAGR (%), 2019, 2025 and 2030 Table 17.2 Global Dermatological Drugs Market by Indication: Revenue ($bn), and Market Share (%), 2019 Table 17.3 Global Dermatological Drugs Market by Region: Revenue ($bn), 2019, 2025, 2030 Table 17.4 Global Dermatological Drugs Market by Indication: Revenue ($Bn), 2020, 2025, 2030 List of Figures Figure 1.1 Global Dermatological Drugs Market Segmentation Overview Figure 2.1 Anatomy of Human Skin Figure 3.1 Global Dermatological Drugs Market by Indication: Market Share (%), 2019 Figure 3.2 World Dermatological Drugs Market: Revenues ($bn), by Indication, 2019 Figure 3.3 Global Dermatological Drugs Market Forecast: Revenue ($bn), AGR (%), 2019-2030 Figure 3.4 The Global Dermatological Drugs Market Forecast by Indication: AGR (%), 2020-2025 Figure 3.5 The Global Dermatological Drugs Market Forecast by Indication: AGR (%), 2025-2030 Figure 3.6 The Global Dermatological Drugs Market Forecast by Indication: AGR(%) 2020-2030 Figure 3.7 Global Dermatological Drugs Market by Indication: Market Share (%), 2020 Figure 3.8 Global Dermatological Drugs Market by Indication: Market Share (%), 2025 Figure 3.9 Global Dermatological Drugs Market by Indication: Market Share (%), 2030 Figure 4.1 World Psoriasis Drugs Market: Revenues ($bn), by Drugs, 2019 Figure 4.2 Global Psoriasis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 4.3 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2019 Figure 4.4 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2025 Figure 4.5 Global Psoriasis Drugs Market by Leading Drugs: Market Share (%), 2030 Figure 4.6 Global Humira Market Forecast: Revenue ($bn) AGR (%), 2010-2017 Figure 4.7 Global Humira Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 4.8 Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2010-2017 Figure 4.9 Global Stelara Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 4.10 Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2009-2017 Figure 4.11 Global Enbrel Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 4.12 Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2009-2017 Figure 4.13 Global Remicade Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 4.14 Global Taltz Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 4.15 Global Otezla Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 4.16 Global Cosentyx Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 4.17 Global Others Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 5.1 World Skin Infection Drugs Market: Revenues ($bn), by Drugs, 2019 Figure 5.2 Global Skin Infection Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 5.3 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2019 Figure 5.4 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2025 Figure 5.5 The Skin Infection Drugs Market by Leading Drugs: Market Share (%), 2030 Figure 5.6 Global Cubicin Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 5.7 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2010-2017 Figure 5.8 Global Zyvox Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 5.9 Global Canesten Market Forecast: Revenue ($bn) AGR (%), 2011-2017 Figure 5.10 Global Canesten Market Forecast: Revenue ($Bn) AGR (%), 2019-2030 Figure 5.11 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2010-2017 Figure 5.12 Global Valtrex Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 5.13 Global Sivexto Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 5.14 Global Lamisil Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 5.15 Global Others Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.1 World Acne Drugs Market: Revenues ($bn), by Drugs, 2019 Figure 6.2 Global Acne Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.3 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2019 Figure 6.4 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2025 Figure 6.5 The Global Acne Drugs Market by Leading Drugs: Market Share (%), 2030 Figure 6.6 Global Epiduo Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.7 Global Solodyn Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.8 Global Claravis Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.9 Global Aczone Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.10 Global Retin-A Micro Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.11 Global Absorica/ Epirus Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.12 Global Ziana Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.13 Global Acanya/Onexton Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 6.14 Global Others Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 7.1 World Dermatitis Drugs Market: Revenues ($bn), by Drugs, 2019 Figure 7.2 Global Dermatitis Drugs Segment Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 7.3 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2019 Figure 7.4 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2025 Figure 7.5 The Global Dermatitis Drugs Market by Leading Drugs: Market Share (%), 2030 Figure 7.6 Global Bepanthen/ Bepanthol Market Forecast: Revenue ($bn), AGR (%), 2019-2030 Figure 7.7 Global Elocon Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 7.8 Global Protopic Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 7.9 Global Dermovate Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 7.10 Global Other Dermatitis Market Forecast: Revenue ($bn) AGR (%), 2019-2030 Figure 8.1 World Dermatological Drugs Market: Revenues ($bn) by Region, 2019 Figure 8.2 World Dermatological Drugs Market: Revenues ($bn) by Region, 2030 Figure 8.3 Global Dermatological Drugs Market Forecast By Region: Revenue ($bn), 2019-2030 Figure 8.4 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2020 Figure 8.5 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2025 Figure 8.6 World Dermatological Drugs Market: Market Shares (%) by Regional Market, 2030 Figure 9.1 North America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 9.2 North America Dermatological Drugs Market: Market Shares (%) by Country, 2019 Figure 9.3 North America Dermatological Drugs Market: Market Shares (%) by Country, 2025 Figure 9.4 North America Dermatological Drugs Market: Market Shares (%) by Country, 2030 Figure 9.5 U.S. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 9.6 Canada Dermatological Drugs Market Forecast: Revenues ($ Bn), AGR (%), 2019-2030 Figure 10.1 Europe Dermatological Drugs Market: Revenues ($bn) by Country/Sub-region, 2019 Figure 10.2 Europe Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030 Figure 10.3 Europe Dermatological Drugs Market: Market Shares (%) by Regional Market, 2019 Figure 10.4 Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2025 Figure 10.5 Europe Dermatological Drugs Market: Market Shares (%) by Country Market, 2030 Figure 10.6 Germany Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 10.7 France Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 10.8 U.K. Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 10.9 Italy Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 10.10 Spain Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 10.11 Rest of Europe Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 11.1 Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 11.2 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2019 Figure 11.3 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2025 Figure 11.4 Asia-Pacific Dermatological Drugs Market: Market Shares (%) by Country, 2030 Figure 11.5 China Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030 Figure 11.6 Japan Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030 Figure 11.7 India Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 11.8 Rest of Asia-Pacific Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 12.1 Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 12.2 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2019 Figure 12.3 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2025 Figure 12.4 Latin America Dermatological Drugs Market: Market Shares (%) by Country Market, 2030 Figure 12.5 Brazil Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030 Figure 12.6 Mexico Dermatological Drugs Market Forecast: Revenues ($ bn), AGR (%), 2019-2030 Figure 12.7 Rest of Latin America Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 13.1 Middle East & Africa (MEA) Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 13.2 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2019 Figure 13.3 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2025 Figure 13.4 Middle East & Africa Dermatological Drugs Market: Market Shares (%) by Country Market, 2030 Figure 13.5 Saudi Arabia Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 13.6 South Africa Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 13.7 Rest of MEA Dermatological Drugs Market Forecast: Revenues ($bn), AGR (%), 2019-2030 Figure 14.1 Johnson & Johnson: Revenue ($m), AGR (%), 2013-2017 Figure 14.2 Johnson & Johnson: Business Segment Revenue Share (%), 2018 Figure 14.3 Johnson & Johnson: Region Revenue Share (%), 2018 Figure 14.4 GlaxoSmithKline plc: Revenue ($m), 2014-2018 Figure 14.5 GlaxoSmithKline plc: Business Segment Revenue Share (%), 2018 Figure 14.6 GlaxoSmithKline plc: Pharmaceutical Business Segment Revenue Share (%), 2018 Figure 14.7 GlaxoSmithKline plc: by Region Revenue Share (%), 2018 Figure 14.8 Pfizer, Inc.: Revenue ($bn), Net Income (Sbn), R&D Investment ($bn), 2019-2018 Figure 14.9 Pfizer, Inc.: Business Segment Revenue Share (%), 2018 Figure 14.10 Pfizer, Inc.: National Revenue Share (%), 2018 Figure 14.11 LEO Pharma A/S : Revenue ($m), AGR (%), 2014-2018 Figure 14.12 LEO Pharma A/S: Therapeutic Area Revenue Share (%), 2018 Figure 14.13 LEO Pharma A/S: Region Revenue Share (%), 2018 Figure 14.14 AbbVie Inc.: Revenue ($m), AGR (%), 2014-2018 Figure 14.15 AbbVie Inc.: Regional Segment Revenue Share (%), 2018 Figure 14.16 Novartis: Revenue ($m), AGR (%), 2014-2018 Figure 14.17 Novartis: Revenue, by Division, Share (%), 2018 Figure 14.18 Novartis: Revenue, by Region, Share (%), 2018 Figure 14.19 Amgen, Inc.: Revenue ($m), AGR (%), 2014-2018 Figure 14.20 Amgen, Inc.: Revenue, by Division, Share (%), 2018 Figure 14.21 Amgen, Inc.: Revenue, by Region, Share (%), 2019 Figure 14.22 Merck & Co., Inc.: Revenue ($m), AGR (%), 2014-2018 Figure 14.23 Merck & Co., Inc.: Business Segment Revenue Share (%), 2018 Figure 14.24 Merck & Co., Inc.: Region Revenue Share (%), 2018 Figure 14.25 Bayer AG: Revenue ($m), AGR (%), 2014-2018 Figure 14.26 Bayer AG: Business Segment Revenue Share (%), 2018 Figure 14.27 Bayer AG: Region Revenue Share (%), 2018 Figure 14.28 Celgene Corporation: Revenue ($m), AGR (%), 2014-2018 Figure 14.29 Celgene Corporation: Regional Segment Revenue Share (%), 2018 Figure 14.30 Bausch Health Companies Inc.: Revenue ($m), AGR (%), 2014-2018 Figure 14.31 Bausch Health Companies Inc.: Regional Segment Revenue Share (%), 2018 Figure 14.32 Bristol-Myers Squibb Company: Revenue ($m), AGR (%), 2014-2018 Figure 14.33 Bristol-Myers Squibb Company: Regional Segment Revenue Share (%), 2018 Figure 14.34 Allergan plc: Revenue ($m), AGR (%), 2014-2018 Figure 14.35 Allergan plc: Regional Segment Revenue Share (%), 2018 Figure 14.36 Eli Lilly and Company: Revenue, Net Income, and R&D Investment ($m), 2014-2018 Figure 14.37 Eli Lilly and Company: Regional Segment Revenue Share (%), 2018 Figure 16.1 Porters Five Force Analysis Figure 17.1 Global Dermatological Drugs Market Forecast: Revenue ($bn) 2017, 2025, 2030 Figure 17.2 World Dermatological Drugs Market: Revenues ($bn), by Indication, 2019 Figure 17.3 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2019, 2025, 2030 Figure 17.4 The Global Dermatological Drugs Market Forecast by Region: Revenue ($bn), 2019, 2025, 2030